IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1	ln.	ro	ar	n	lica:	tion	Of.
4			uμ	Υ.	IIVU		٠

Angel CEBOLLA RAMIREZ et al Atty. Docket No. 027318-00021

Serial No.: New Application

Examiner:

Filed: May 30, 2006

Art Unit:

METHOD OF REGULATING HETEROLOGOUS PROTEIN EXPRESSION CONTROLLED BY SALICYLIC DERIVATIVES IN MICRO-ORGANISMS

ASSOCIATED WITH HIGHER ORGANISMS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Date: May 30, 2006

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached Form PTO-SB08. Unless otherwise indicated herein, one copy of each item(s) is attached. respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

		.5	,,
\boxtimes	merits	U.S. filing in the p	formation Disclosure Statement is being filed (a) within three months ng date, OR (b) before the mailing date of a first Office Action on the resent application, OR (c) accompanies a Request for Continued No certification or fee is required.
		he U.S.	formation Disclosure Statement is being filed more than three months filing date AND after the mailing date of the first Office Action on the fore the mailing date of a Final Rejection or Notice of Allowance.
		foreign	I hereby certify that each item of information contained in this ation Disclosure Statement was first cited in a communication from a patent office in a counterpart foreign application not more than three is prior to the filing of this Information Disclosure Statement. 37 CFR e)(1).
		office i reasor	I hereby certify that no item of information in this Information sure Statement was cited in a communication from a foreign patent in a counterpart foreign application or, to my knowledge after making lable inquiry, was known to any individual designated in 37 CFR c) more than three months prior to the filing of this Information

Disclosure Statement. 37 CFR §1.9 CPC PIPE 30 MAY 2006 c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information. 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that

a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).

the Information Disclosure Statement be considered. Attached is our check in the amount of \$180.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300

as needed to ensure consideration of the disclosed information.

- b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).
- 4. The reference(s) was/were cited in a counterpart foreign application. An English language version of the foreign search report is attached for the Examiner's information.

Respectfully submitted,

Richard JV Berman Registration No. 39,107

Customer No. 004372 ARENT FOX PLLC 1050 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339

Tel: (202) 857-6000 Fax: (202) 638-4810

RJB/ars

Enclosures: International Search Report; Form PTO-SB08a; References (6)

AP20 ROS OF THE 0 30 MAY 2006

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1 to a collection of information unless it contains a valid OMB control number.

	U	Inder the Paperwork H	deauctic	on Ac	it of 1995, no persons ar	e required to respond to a collection	on or information unless it contains a valid OMB control number.	
	Substit	ute for form 1449A/PT	0			Complete if Known		
	INFORMATION DISCLOSURE					Application Number	New Application 20102	
						Filing Date	May 30, 2006	
	STATEMENT BY APPLICANT Form PTO/SB/08a					First Named Inventor	Angel CEBOLLA RAMIREZ et al	
						Art Unit		
						Examiner Name		
Sheet		1	0	f	1	Attorney Docket Number	027318-00021	

			U.S. PA	ATENT DOC	JMENTS	
Examiner Initials*	Cite No.1	Document Number	Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US- 2003/0113293	A1	06-19-2003	David G. BERMUDES et al	
		US-2001/0016354	A1	08-23-2001	Angel CEBOLLA RAMIREZ et al	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
-		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
	1	US-				
	1	US-				
		US-				
	1	US-				

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document	Country Code ³	Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	ಗ್	
	1	03063593	wo	Α	08-07-2003	Vion Pharmaceuticals, Inc.			
	l								
	 		l				-		
	 								
-	1		-						
	 								
	 		-						
	 			-	· · · · · · · · · · · · · · · · · · ·				
	 								

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

PTO/SB/08b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO Complete if Known. New Application 20 4 4 6 2 **Application Number** INFORMATION DISCLOSURE May 30, 2006 Filing Date STATEMENT BY APPLICANT Angel CEBOLLA RAMIREZ et al First Named Inventor Form PTO/SB/08b Art Unit **Examiner Name** Attorney Docket Number 027318-00021 Sheet 1

		NAME OF THE OWNER OWNER OF THE OWNER O					
NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²				
		M.C. SULAVIK et al; The Salmonella Typhimurium Mar Locus; Molecular and Genetic Analyses and Assessment of its Role in Virulence; J. Bactoriol., 1997; Vol. 179; No. 6; pages 1857-1866.					
		J.M. PAWELEK et al; Bacteria as Tumour-Targeting Vectors; Lancet Oncol; 2003; Vol. 4; No. 9; pages 548-556.					
		A. CEBOLLA et al; Rational Design of a Bacterial Transcriptional Cascade for Amplifying Gene Expression Capacity; Nucleic Acids Res; 2001; Vol. 29; No. 3; pages 759-766					
		A. CEBOLLA et al; Improvement of Recombinant Protein Yield by a Combination of Transcriptional Amplification and Stabilization of Gene Expression; <i>Appl. Environ. Microbiol</i> ; 2002; Vol. 68; No. 10; pages 5034-5041.					
		S. P. COHEN et al; Salicylate Induction of Antibiotic Resistance in Escherichia Coli; Activation of the Mar Operon and A Mar-Independent Pathway; <i>J. Bacteriol</i> ; 1993; Vol. 175; No. 24; pages 7856-7862					
_							
-,							
	1						

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.